Biologics Sales 2009: Antibodies are the growth drivers
Double digit growth rates in classes of antibodies and selected proteins
La Merie S.L. released the new compilation of biologics sales in 2009. In its fourth edition, the report showed again that cancer antibodies and anti-TNF antibodies were leading the field. Sales of insulins grew by 22.4% and consolidated its 3rd position in the ranking list due to the outstanding success of insulin analogs. The mature protein classes erythropoietins,G-CSF, interferon alpha, FSH and ERTs stagnated or even shrank. Sales of interferonbeta and coagulation factors grew with 13% and 16%, respectively.
Among the 28 blockbuster biologics with 2009 sales of more than US$ 1 bln, the ophthalmic antibodyLucentis achieved the highest growth rate (+33% vs 2008) followed by the multiplesclerosis antibody Tysabri (+30%) and the insulin analogs Lantus (+22.5%) and NovoLog/NovoRapid (+22%). Anti-inflammatory antibodies different from anti-TNF were newly introduced as a class of biologics due to their strong growth potential (+36.5% vs 2008).
Biosimilar sales reported by Sandoz (US$ 118 mln) had no impact on 2009biologics sales, but showed a growth rate of 73%. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report on March 12, 2010.
The document entitled “TOP 20 Biologics 2009” can be acquired as a free download.
Most read news
Organizations
Related link
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous